indolent NHL
Showing 1 - 25 of 887
CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)
Terminated
- CD20-positive Non-Hodgkin Lymphoma
- Rituximab + MG4101
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 24, 2022
Severe COVID-19 Infection in CLL or B-NHL Who Received
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- (no location specified)
Apr 6, 2023
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma
Completed
- Follicular Lymphoma (FL/Indolent NHL)
- +4 more
- Cerdulatinib
- Rituximab
-
Huntsville, Alabama
- +22 more
Apr 1, 2022
Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))
Completed
- Lymphoma Non-Hodgkin
- Copanlisib (BAY80-6946)
-
Nagoya, Aichi, Japan
- +12 more
Feb 21, 2022
Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)
Active, not recruiting
- Indolent B-cell Non-Hodgkin's Lymphoma
-
Anjo, Aichi, Japan
- +29 more
Dec 10, 2021
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical
Completed
- Multiple Myeloma
- +7 more
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Nov 2, 2022
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent
Completed
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- +9 more
- Lenalidomide
- Rituximab
-
Houston, TexasM D Anderson Cancer Center
Sep 28, 2021
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Non-Hodgkin's Lymphoma Trial in United States (fludarabine and rituximab, fludarabine, rituximab, pixantrone)
Withdrawn
- Non-Hodgkin's Lymphoma
- fludarabine and rituximab
- fludarabine, rituximab, pixantrone
-
Muscle Shoals, Alabama
- +7 more
Oct 2, 2020
Hematological Malignancies Trial in Beijing, Tianjin (TQB3820 tablets)
Recruiting
- Hematological Malignancies
- TQB3820 tablets
-
Beijing, Beijing, China
- +1 more
Sep 18, 2021
Refractory Indolent Adult Non-Hodgkin Lymphoma Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T)
Recruiting
- Refractory Indolent Adult Non-Hodgkin Lymphoma
- CD19 CAR-T
- +4 more
-
Shijiazhuang, Hebei, ChinaNo.2 Hospital of Hebei Medical University
Nov 11, 2020
Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)
Recruiting
- Follicular Lymphoma
- Marginal Zone Lymphoma
- EO2463
- +2 more
-
Boston, Massachusetts
- +9 more
Jul 26, 2022
Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,
Recruiting
- Follicular B-cell Non-Hodgkin's Lymphoma
- +7 more
- MB-106
-
Orange, California
- +3 more
Nov 1, 2022
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (Aliqopa, BAY80-6946))
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (Aliqopa, BAY80-6946)
-
Birmingham, Alabama
- +100 more
Feb 10, 2022
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))
Active, not recruiting
- Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
- Blinatumomab Expanded T-cells (BET)
-
Bergamo, ItalyASST - Papa Giovanni XXIII
Dec 22, 2021
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg
Recruiting
- B-cell Non Hodgkin Lymphoma
- B-cell Chronic Lymphocytic Leukemia
- Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
- +3 more
-
Milwaukee, WisconsinMedical College of Wisconsin and Froedtert Hospital
Jul 1, 2022
Follicular Lymphoma (FL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +6 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
B-Cell Lymphoid Malignancies, Hematologic Malignancy, Non-Hodgkin Lymphoma Trial in Miami (Hematopoietic Stem Cells from
Recruiting
- B-Cell Lymphoid Malignancies
- +2 more
- Hematopoietic Stem Cells from HLA-compatible Related
- Hematopoietic Stem Cells from HLA Unrelated
-
Miami, FloridaMiami Cancer Institute at Baptist Health of South Florida
May 5, 2022
